Stock-Based Compensation: The estimated market value of stock options, warrants and other stock-based compensation given to employees and/or vendors.
Helix Biopharma Corp. (HBPCF) had Stock-Based Compensation of $0.11M for the most recently reported fiscal quarter, ending 2025-04-30.
| Income Statement Financials | |
-- |
|
$-1.09M |
|
-- |
|
-- |
|
$1.09M |
|
$-1.09M |
|
$0.01M |
|
$-1.09M |
|
$-1.09M |
|
$-1.09M |
|
$-1.09M |
|
$-1.09M |
|
$-1.09M |
|
$-1.09M |
|
$-1.09M |
|
53.04M |
|
53.04M |
|
$-0.02 |
|
$-0.02 |
|
| Balance Sheet Financials | |
$0.71M |
|
$0.00M |
|
$0.00M |
|
$0.71M |
|
$1.69M |
|
-- |
|
-- |
|
$1.69M |
|
$-0.98M |
|
$-0.98M |
|
$-0.98M |
|
53.15M |
|
| Cash Flow Statement Financials | |
$-2.24M |
|
$0.01M |
|
$1.97M |
|
$0.76M |
|
$0.50M |
|
$-0.26M |
|
|
Stock-Based Compensation |
$0.11M |
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
0.42 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-2.23M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
111.08% |
|
111.08% |
|
-153.02% |
|
111.08% |
|
$-0.02 |
|
$-0.04 |
|
$-0.04 |
|